Cardiovascular disease as a complication of community-acquired pneumonia

Current Opinion in Pulmonary Medicine

Volumn 22, Issue 3, 2016, Pages 212-218

  Rae, Nikolas ^a   Finch, Simon ^b   Chalmers, James D ^b  

^a NINEWELLS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

cardiac; mortality; pneumonia; statins; streptococcus

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; CARDIOVASCULAR AGENT; MACROLIDE; PNEUMOLYSIN;

ACUTE HEART INFARCTION; ANTIBIOTIC THERAPY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHLAMYDIAL PNEUMONIA; COMMUNITY ACQUIRED PNEUMONIA; COMMUNITY CARE; DRUG SAFETY; HEART FAILURE; HEART MUSCLE; HEART MUSCLE FIBROSIS; HEART PROTECTION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LOW RISK PATIENT; MORBIDITY; PNEUMOCOCCAL INFECTION; PROGNOSIS; QT PROLONGATION; RESPIRATORY TRACT INFECTION; REVIEW; STREPTOCOCCUS PNEUMONIAE; SUDDEN CARDIAC DEATH; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS; TREATMENT OUTCOME; ANIMAL; CARDIOVASCULAR DISEASES; COMMUNITY ACQUIRED INFECTION; COMPLICATION; MICROBIOLOGY; PNEUMONIA; RISK FACTOR;

ANIMALS; BIOMARKERS; CARDIOVASCULAR DISEASES; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; MORBIDITY; PNEUMONIA; PROGNOSIS; RISK FACTORS;

EID: 84958824659     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000261     Document Type: Review

References (53)

1. Office for National Statistics UK, http://www.ons.gov.uk/ons/rel/vsob1/mor-tality-statistics-deaths-registered-in-england-and-wales-series-dr-/2012/sty-causes-of-death.html. [Accessed 10 December 2015]
2. Choudhury G, Chalmers JD, Mandal P, et al. Physician judgement is a crucial adjunct to pneumonia severity scores in low risk patients. Eur Respir J 2011; 38:643-648.
3. Singanayagam A, Chalmers JD. The evidence for severity assessment tools to guide empirical antibiotic prescribing decisions in community-acquired pneumonia. Lancet Respir Med 2013; 1:653-662.
4. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44:S27-S72.
5. Corrales-Medina VF, Musher DM, Shachkina S, Chirinos JA. Acute pneumonia and the cardiovascular system. Lancet 2013; 381:496-505.
6. Singanayagam A, Singanayagam A, Elder DH, Chalmers JD. Is community-acquired pneumonia an independent risk factor for cardiovascular disease? Eur Respir J 2011; 39:187-196.
7. Yende S, Angus DC, Ali IS, et al. Influence of comorbid conditions on long term mortality after pneumonia in older people. J Am Geriatr Soc 2007; 55:518-525.
8. Aliberti S, Cillonez C, Chalmers JD, et al. Multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia: a European perspective. Thorax 2013; 68:997-999.
9. Johnstone J, Eurich DT, Majumdar SR, et al. Long-term morbidity and mortality after hospitalization with community-acquired pneumonia: a population-based cohort study. Medicine 2008; 87:329-334.
10. Torres A, Blasi F, Dartois N, Akova M. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax 2015; 70:984-989.
11. Chalmers JD, Rother C, Salih W, Ewig S. Healthcare associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. Clin Infect Dis 2014; 58:330-339.
12. Waterer GW, Kessler LA, Wunderink RG. Medium-term survival after hospi-talization with community-acquired pneumonia. Am J Respir Crit Care Med 2004; 169:910-914.
13. Mortensen EM, Kapoor WN, Chang CC, Fine MJ. Assessment of mortality after long-term follow-up of patients with community-acquired pneumonia. Clin Infect Dis 2003; 37:1617-1624.
14. Restrepo MI, Faverio P, Anzueto A. Long term prognosis in community-acquired pneumonia. Curr Opin Infect Dis 2013; 26:151-158.
15. Bordon J, Wiemken T, Peyrani P, et al. Decrease in long-term survival for hospitalised patients with community-acquired pneumonia. Chest 2010; 138:248-249.
16. Meier CR, Jick SS, Derby LE, et al. Acute respiratory-tract infections and risk of first-time acute myocardial infarction. Lancet 1998; 351:1467-1471.
17. Smeeth L, Thomas SL, Hall AJ, et al. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004; 351:2611-2618.
18. Clayton TC, Thompson M, Meade TW. Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database. Eur Heart J 2008; 29:96-103.
19. Musher DM, Rueda AM, Kaka AS, Mapara SM. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis 2007; 45:158-165.
20. Becker T, Moldoveanu A, Cukierman T, Gerstein HC. Clinical outcomes associated with the use of subcutaneous insulin-by-glucose sliding scales to manage hyperglycemia in hospitalized patients with pneumonia. Diabetes Res Clin Pract 2007; 78:392-397.
21. Ramirez J, Aliberti S, Mirsaeidi M, et al. Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis 2008; 47:182-187.
22. Corrales-Medina VF, Serpa J, Rueda AM, et al. Acute bacterial pneumonia is associated with the occurrence of acute coronary syndromes. Medicine (Baltimore) 2009; 88:154-159.
23. Corrales-Medina VF, Musher DM, Wells GA, et al. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors and association with short-term mortality. Circulation 2012; 125:773-781.
24. Mandal P, Chalmers JD, Choudhury G, et al. Vascular complications are associated with poor outcome in community-acquired pneumonia. QJM 2011; 104:489-495.
25. Cangemi R, Calvieri C, Falcone M, et al. Relation of cardiac complications in the early phase of community-acquired pneumonia to long-term mortality and cardiovascular events. Am J Cardiol 2015; 116:647-651.
26. Corrales-Medina VF, Suh KN, Rose G, et al. Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. PLoS Med 2011; 8:e1001048.
27. Griffin AT, Wiemken TL, Arnold FW. Risk factors for cardiovascular events in hospitalized patients with community-acquired pneumonia. Int J Infect Dis 2013; 17:e1125-e1129.
28. Corrales-Medina VF, Alvarez KN, Weissfeld LA, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA 2015; 313:264-274.
29. Yende S, D'Angelo G, Kellum JA, et al. GenIMS Investigators. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med 2008; 177:1242-1247.
30. Chang CL, Mills GD, Karalus NC, et al. Biomarkers of cardiac dysfunction and mortality from community-acquired pneumonia in adults. PLoS One 2013; 8:e62612.
31. Nowak A, Breidthardt T, Christ-Crain M, et al. Direct comparison of three natriuretic peptides for prediction of short-and long-term mortality in patients with community-acquired pneumonia. Chest 2012; 141:974-982.
32. Yende S, D'Angelo G, Mayr F, et al. Elevated hemostasis markers after pneumonia increases one-year risk of all-cause and cardiovascular deaths. PLoS One 2011; 6:e22847.
33. Madjid M, Vela D, Khalili-Tabrizi H, et al. Systemic infections cause exaggerated local inflammation in atherosclerotic coronary arteries: clues to the triggering effect of acute infections on acute coronary syndromes. Tex Heart Inst J 2007; 34:11-18.
34. Merx MW, Weber C. Sepsis and the heart. Circulation 2007; 116:793-802.
35. Cangemi R, Casciaro M, Rossi E, et al. Platelet activation is associated with myocardial infarction in patients with pneumonia. J Am Coll Cardiol 2014; 64:1917-1925.
36. Violi F, Carnevale R, Calvieri C, et al. Nox2 up-regulation is associated with an enhanced risk of atrial fibrillation in patients with pneumonia. Thorax 2015; 70:961-966.
37. Brown AO, Mann B, Gao G, et al. Streptococcus pneumoniae translocates into the myocardium and forms unique microlesions that disrupt cardiac function. PLoS Pathog 2014; 10:e1004383.
38. Brown AO, Millett ER, Quint JK, Orihuela CJ. Cardiotoxicity during invasive pneumococcal disease. Am J Respir Crit Care Med 2015; 191:739-745.
39. Alhamdi Y, Neill Dr, Abrams ST, et al. Circulating pneumolysin is a potent inducer of cardiac injury during pneumococcal infection. PLoS Pathog 2015; 11:e1004836.
40. Postma DF, van Werkhoven CH, van Elden LJ, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 2015; 372:1312-1323.
41. Garin N, Genne D, Carballo S, et al. b-Lactam monotherapy vs b-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med 2014; 174:1894-1901.
42. Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004; 351:1089-1096.
43. Jespersen CM, Als-Nielsen B, Damgaard M, et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ 2006; 332:22-27.
44. Schembri S, Williamson PA, Short PM, et al. Cardiovascular events following Clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ 2013; 346:f1235.
45. Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366:1881-1890.
46. Svanstrom H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med 2013; 368:1704-1712.
47. Mortensen EM, Halm EA, Pugh MJ, et al. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. JAMA 2014; 311:2199-2208.
48. Cheng YJ, Nie XY, Chen XM, et al. The role of macrolide antibiotics in increasing cardiovascular risk. J Am Coll Cardiol 2015; 66:2173-2184.
49. Goldstein LH, Gabin A, Fawaz A, et al. Azithromycin is not associated with QT prolongation in hospitalized patients with community-acquired pneumonia. Pharmacoepidemiol Drug Saf 2015; 24:1042-1048.
50. Chopra V, Rogers MA, Buist M, et al. Is statin use associated with reduced mortality after pneumonia? A systematic review and meta-analysis. Am J Med 2012; 125:1111-1123.
51. Chalmers JD, Singanayagam A, Murray MP, Hill AT. Prior statin use is associated with improved outcomes in community acquired pneumonia. Am J Med 2008; 121:1002-1007; e1.
52. Mortensen EM, Pugh MJ, Copeland LA, et al. Impact of statins and angio-tensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur Respir J 2008; 31:611-617.
53. Oz F, Gul S, Kaya MG, et al. Does aspirin use prevent acute coronary syndrome in patients with pneumonia. Multicenter prospective randomized trial. Coron Artery Dis 2013; 24:231-237.